Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep;94(9):4047-4052.
doi: 10.1002/jmv.27836. Epub 2022 May 16.

Immunogenicity and safety of different platforms of COVID-19 vaccines given as a third (booster) dose in healthy adults

Zemin Lin  1 , Mengnan Cheng  1 , Fenghua Zhu  1 , Xiaoqian Yang  1 , Jianping Zuo  1   2   3 , Shijun He  1   2
Affiliations
Comment

Immunogenicity and safety of different platforms of COVID-19 vaccines given as a third (booster) dose in healthy adults

Zemin Lin et al. J Med Virol. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Forest plot for any Grade 3 or 4 adverse event with relative risk random effects. Grades 3 and 4 among 3990 participants who have previously received BNT162b2/BNT162b2 or AZD1222/AZD1222 vaccination were assigned a different booster vaccination or some trial treatment. CI, confidence interval, M‐H, Mantel–Haenszel.
See this image and copyright information in PMC

Comment on

References

    1. Ai J, Zhang Y, Zhang H, et al. Safety and immunogenicity of a third‐dose homologous BBIBP‐CorV boosting vaccination: interim results from a prospective open‐label study. Emerg Microbes Infect. 2022;11(1):639‐647. - PMC - PubMed
    1. Petrelli F, Luciani A, Borgonovo K, et al. Third dose of SARS‐CoV‐2 vaccine: A systematic review of 30 published studies. J Med Virol. 2022;94:2837‐2844. - PMC - PubMed
    1. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID‐19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov‐19 or BNT162b2 in the UK (COV‐BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258‐2276. - PMC - PubMed
    1. Intapiboon P, Seepathomnarong P, Ongarj J, et al. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS‐CoV‐2 vaccine in healthy population. Vaccines‐Basel. 2021;9(12):1375. - PMC - PubMed
    1. Kanokudom S, Assawakosri S, Suntronwong N, et al. Safety and Immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID‐19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines‐Basel. 2022;10(1):86. - PMC - PubMed